Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMTS0929 for Inflammatory Bowel Disease
NCT06844708Phase 1Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Nanjing Medical University
- Start
- Feb 2025
- Primary completion
- Jan 2030
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CMTS0929 in inflammatory bowel disease (IBD), sponsored by The Second Affiliated Hospital of Nanjing Medical University. Primary endpoint: Efficacy of CMTS0929 at 4 weeks. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
CMTS0929
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT06844708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06844708.